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Triple Versus Dual Antiplatelet Therapy in Patients With
Acute ST-Segment Elevation Myocardial Infarction
Undergoing Primary Percutaneous Coronary Intervention
Kang-Yin Chen, MD; Seung-Woon Rha, MD; Yong-Jian Li, MD; Kanhaiya L. Poddar, MBBS;
Zhe Jin, MD; Yoshiyasu Minami, MD; Lin Wang, MD; Eung Ju Kim, MD; Chang Gyu Park, MD;
Hong Seog Seo, MD; Dong Joo Oh, MD; Myung Ho Jeong, MD; Young Keun Ahn, MD;
Taek Jong Hong, MD; Young Jo Kim, MD; Seung Ho Hur, MD; In Whan Seong, MD;
Jei Keon Chae, MD; Myeong Chan Cho, MD; Jang Ho Bae, MD; Dong Hoon Choi, MD;
Yang Soo Jang, MD; In Ho Chae, MD; Chong Jin Kim, MD; Jung Han Yoon, MD;
Wook Sung Chung, MD; Ki Bae Seung, MD; Seung Jung Park, MD;
for the Korea Acute Myocardial Infarction Registry Investigators
Background—Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute
ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in the era of
drug-eluting stents remains unclear.
Methods and Results—A total of 4203 ST-segment elevation myocardial infarction patients who underwent primary
percutaneous coronary intervention with drug-eluting stents were analyzed retrospectively in the Korean Acute
Myocardial Infarction Registry (KAMIR). They received either dual (aspirin plus clopidogrel; dual group; n2569) or
triple (aspirin plus clopidogrel plus cilostazol; triple group; n1634) antiplatelet therapy. The triple group received
additional cilostazol at least for 1 month. Various major adverse cardiac events at 8 months were compared between
these 2 groups. Compared with the dual group, the triple group had a similar incidence of major bleeding events but a
significantly lower incidence of in-hospital mortality. Clinical outcomes at 8 months showed that the triple group had
significantly lower incidences of cardiac death (adjusted odds ratio, 0.52; 95% confidence interval, 0.32 to 0.84;
P0.007), total death (adjusted odds ratio, 0.60; 95% confidence interval, 0.41 to 0.89; P0.010), and total major
adverse cardiac events (adjusted odds ratio, 0.74; 95% confidence interval, 0.58 to 0.95; P0.019) than the dual group.
Subgroup analysis showed that older (65 years old), female, and diabetic patients got more benefits from triple
antiplatelet therapy than their counterparts who received dual antiplatelet therapy.
Conclusions—Triple antiplatelet therapy seems to be superior to dual antiplatelet therapy in patients with ST-segment
elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. These
results may provide the rationale for the use of triple antiplatelet therapy in these patients. (Circulation. 2009;119:3207-3214.)
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Drug-eluting stents (DES) have drastically changed thelandscape of percutaneous coronary intervention (PCI),
with significant reductions in the angiographic restenosis rate
and need for repeated revascularization.1 However, several
studies showed that DES is associated with a higher incidence
of in-stent thrombosis compared with bare metal stents.2,3
Therefore, the latest guideline for antiplatelet therapy after
PCI with DES suggests that the dual antiplatelet therapy
(aspirin plus clopidogrel) be administered for at least 12
months.3 But is it enough for high-risk patients? Some studies
showed that as many as 50% of the patients who received PCI
did not react positively to aspirin or clopidogrel.4–6 Further-
more, there is increased platelet activity in acute coronary
syndrome, especially in acute myocardial infarction (AMI).7
Editorial see p 3168
Clinical Perspective on p 3214
Cilostazol is a potent inhibitor of type III phosphodiester-
ase in both platelets and vascular smooth muscle cells.8–10
The antiplatelet effect of cilostazol is 10 to 30 times more
potent than that of aspirin.9 Antiplatelet therapy with cilosta-
zol after PCI has similar safety and efficacy outcomes
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compared with aspirin or clopidogrel.11–13 A recent study
suggested that cilostazol could ameliorate platelet responsive-
ness to clopidogrel in patients who underwent primary PCI.14
Furthermore, some other studies showed that the administra-
tion of cilostazol after PCI could significantly lower the
incidence of in-stent restenosis.15–18
Therefore, the present study was designed to evaluate the
safety and efficacy of additional administration of cilostazol
with aspirin and clopidogrel in a real-world cardiology
practice among patients presenting with acute ST-segment
elevation myocardial infarction (STEMI) who received pri-
mary PCI with DES.
Methods
Korea Acute Myocardial Infarction Registry
The Korea Acute Myocardial Infarction Registry (KAMIR) is a
Korean prospective multicenter online registry designed to reflect the
“real-world” practice in Asian patients presenting with AMI in the
DES era, with support from the Korean Circulation Society since
November 2005. Online registry of AMI (at www.kamir.or.kr) has
been performed at 41 university or community hospitals that are
high-volume centers with facilities for primary PCI and onsite
cardiac surgery. Before the initiation of the KAMIR study, several
investigator meetings were held, and a practical steering committee
from major enrolled hospitals was selected to standardize care given
in clinical practice as well as the study protocol to minimize the
differences in medical care among the different hospitals and across
the different time periods. Data were collected at each site by a
trained study coordinator using a standardized case report form.
Standardized definitions of all patient-related variables and clinical
diagnoses were used. The study protocol was approved by the ethics
committee at each participating institution. Data were registered and
submitted from individual institutions via password-protected
Internet-based electronic case report forms. We enrolled patients
who were suffering from AMI, including both STEMI and non-
STEMI. Patients were diagnosed with STEMI when they had new or
presumed new ST-segment elevation of at least 1 mm seen in any
location or new left bundle-branch block on the index or subsequent
ECG with at least 1 positive cardiac biochemical marker of necrosis
(including creatine kinase-MB and troponin I and T).
Study Population
From November 2005 to December 2007, a total of 13 632 patients
were diagnosed with AMI. In the present study, we retrospectively
enrolled patients with acute STEMI who underwent primary PCI
(PCI performed within 24 hours after the symptom onset) with DES.
The criteria for exclusion included non-STEMI, STEMI undergoing
primary PCI with bare metal stent or balloon angioplasty only,
STEMI undergoing selective PCI or conservative treatment without
PCI, Killip grade IV cardiac function, contraindication to antithrom-
botic agents, known bleeding disorders, thrombocytopenia (100109/L),
administration of oral anticoagulants, administration of thrombolytic
or fibrinolytic medications for STEMI, infarction related to the
grafted vessel, severe hepatic or renal dysfunction (serum creatinine
2 mg/dL), and estimated life expectancy of 12 months.
Patients were divided into 2 groups: a dual antiplatelet therapy
group (aspirin plus clopidogrel; dual group; n2569) and a triple
antiplatelet therapy group (aspirin plus clopidogrel plus cilostazol;
the triple group; n1634). Loading doses of aspirin and clopidogrel
were administered immediately after the patients agreed to receive
PCI. The loading and maintenance doses were 200 and 100 mg QD
for aspirin and 300 to 600 and 75 mg QD for clopidogrel. Cilostazol
was given right after the PCI procedure; its loading and maintenance
doses were 200 and 100 mg BID, respectively. According to the
KAMIR study design, AMI patients when discharged were pre-
scribed medicines for 1 month, after which the first follow-up was
performed. Dual antiplatelet therapy was administered to all patients
for 6 months as per existing guidelines. Cilostazol was adminis-
tered to the triple antiplatelet therapy group for at least 1 month after
the index procedure. After discontinuation of cilostazol, the patients
in the triple group received dual antiplatelet therapy.
PCI Procedure and Medical Treatment
Diagnostic angiography and PCI were performed after unfraction-
ated heparin (50 to 70 U/kg) was administered. Coronary angiogra-
phy was performed through the femoral or radial artery. During the
procedure, patients received unfractionated heparin to maintain an
activated clotting time of 250 seconds. Stents were deployed after
prior balloon angioplasty, and the administration of platelet glyco-
protein IIb/IIIa receptor blockers was left to the decision of the
individual operator. A successful PCI procedure was defined as the
achievement of an angiographic minimum stenosis diameter reduc-
tion to 30% in the presence of Thrombolysis in Myocardial
Infarction grade III flow.
During the in-hospital period, patients received medical treatment
that included -blockers, angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, calcium channel blockers, and
statins. After discharge, the patients continued receiving the same
kinds of medications that they received in hospital except some
intravenous or temporary medications.
Study Definitions and Clinical Follow-Up
The records of cardiovascular risk factors and past history (age, sex,
hypertension, dyslipidemia, smoking, diabetes mellitus, family his-
tory of coronary heart disease, prior myocardial infarction, chronic
heart failure and prior cerebrovascular disease, peripheral arterial
disease) were dependent mainly on the patient’s self-report, but the
final records were left to the physician’s discretion after he or she
comprehensively considered the patient’s self-report and the in-
hospital examination results. All deaths were considered cardiac
deaths if noncardiac death could be excluded. Recurrent myocardial
infarction was defined as recurrent symptoms with new ST-segment
elevation or re-elevation of cardiac markers to at least twice the
KAMIR Study (November 2005-December 2007)
13,632 patients were diagnosed with AMI
5,961 STEMI patients underwent primary PCI
Patients excluded:
977 patients who had Killips grade 
IV cardiac function, or received 
BMS or balloon angioplasty only
5,181 STEMI patients who underwent primary PCI 
matched above criteria
Patients excluded:
781 patients who received neither 
dual nor triple antiplatelet therapy, 
or had any other severe diseases
Study population:
4,203 patients underwent primary PCI with DES
Figure 1. Study flow chart. BMS indicates bare metal stents.
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upper limit of normal. Target lesion revascularization (TLR) was
defined as ischemia-induced PCI of the target lesion resulting from
restenosis or reocclusion within the stent or in the adjacent 5 mm of
the distal or proximal segment. Total major adverse cardiac events
(MACEs) were defined as the composite of all-cause death, nonfatal
myocardial infarction, and repeated PCI or coronary artery bypass
grafting. Major bleeding was defined as any intracranial bleeding,
bleeding associated with the need for blood transfusion, or any other
clinically relevant bleeding as judged by the investigator.
Patients were required to visit the outpatient clinic of the cardiol-
ogy department at the end of the first month, every 6 months after the
PCI procedure, and when angina-like symptoms occurred. The
6-month clinical follow-up was done at a median of 173 days
(interquartile range, 147 to 206 days). Therefore, in the present
study, we collected the clinical follow-up data at 8 months (240
days) to ensure that all patients finished their 6-month follow-up.
The incidences of major bleeding events and various MACEs, in
hospital and at 8 months, were evaluated between the dual and triple
groups.
Statistical Analysis
For continuous variables, differences between groups were evaluated
by unpaired t test or Mann-Whitney rank-sum test. For discrete
variables, differences were expressed as counts and percentages and
were analyzed with 2 (or Fisher exact) test between groups as
appropriate. To adjust for potential confounders, a propensity score
analysis was performed using the logistic regression model, testing
the propensity to receive triple rather than dual antiplatelet therapy.
We tested all available variables that could be of potential relevance:
age, sex, Killip class on admission, cardiovascular risk factors
(hypertension, dyslipidemia, smoking, diabetes mellitus, family his-
tory of coronary heart disease), prior myocardial infarction, chronic
heart failure and prior cerebrovascular disease, peripheral arterial
disease, stent type, number of diseased vessels, and cardiovascular
medications (glycoprotein IIb/IIIa receptor blockers, heparins, an-
giotensin-converting enzyme inhibitors, angiotensin II receptor
blockers, -blockers, calcium channel blockers, and statins). The
logistic model by which the propensity score was estimated showed
good predictive value (C statistic0.753). Multivariable Cox regres-
sion analysis was then performed using the propensity score,
antiplatelet therapies (triple versus dual), and the aforementioned
variables to determine the impact of the different antiplatelet
therapies on in-hospital and 8-month clinical outcomes. In addition,
the effects of the different antiplatelet therapies on 8-month clinical
outcomes were further evaluated in different subgroups of patients,
including old (65 years of age), young (65 years of age), male,
female, diabetic, and nondiabetic patients. Cox regression models
adjusted for propensity score and the aforementioned variables were
used to assess odds ratios for various MACEs in these different
subgroups of patients. All continuous variables were described as
meanSD. All analyses were 2-tailed, with clinical significance
defined as values of P0.05. All statistical processes were done with
SPSS 13.0 (Statistical Package for the Social Sciences, SPSS-PC Inc,
Chicago, Ill).
Results
Eligibility is reported in Figure 1. A total of 4203 eligible
STEMI patients who underwent primary PCI with DES were
enrolled, and they represented 71.1% of the 5961 STEMI
patients who underwent primary PCI. As shown in Table 1,
The triple and dual groups had similar baseline clinical






Age, y 62.0112.91 61.9712.41 0.928
Body mass index, kg/m2 24.053.18 23.973.18 0.442
Male, n (%) 1917 (74.6) 1224 (74.9) 0.834
History, n (%)
Hypertension 1165 (45.3) 716 (43.8) 0.331
Diabetes mellitus 629 (24.5) 390 (23.9) 0.649
Current smoking 1265 (49.2) 795 (48.7) 0.930
Dyslipidemia 207 (8.1) 116 (7.1) 0.479
Family history of CAD 190 (7.4) 98 (6.0) 0.216
Prior myocardial infarction 107 (4.2) 75 (4.6) 0.509
Chronic heart failure 19 (0.7) 13 (0.8) 0.839
Peripheral arterial disease 30 (1.2) 12 (0.7) 0.169
Cerebrovascular disease 135 (5.3) 81 (5.0) 0.670
Peptic ulcer disease 8 (0.3) 2 (0.1) 0.334
Killip class, n (%) 0.256
I 2019 (78.6) 1314 (80.4)
II 393 (15.3) 220 (13.5)
III 157 (6.1) 100 (6.1)
Onset to PCI (IQR), h 4.08 (1.75–9.00) 4.08 (1.71–9.01) 0.937
CAD indicates coronary artery disease; IQR, interquartile range.






Target lesion, n (%) 0.215
LAD 1387 (54.0) 866 (53.0)
RCA 919 (35.1) 576 (35.3)
LCx 242 (9.4) 169 (10.3)
Left main 21 (0.8) 23 (1.4)
Diseased vessels, n (%) 0.005
Single 1207 (47.1) 808 (49.4)
Double 790 (30.8) 471 (28.8)
Triple 540 (21.0) 316 (19.4)
Left main disease 30 (1.2) 39 (2.4)
Preprocedure TIMI flow grade,
n (%)
0.170
0 1536 (59.8) 962 (58.9)
I 288 (11.2) 167 (10.2)
II 329 (12.8) 248 (15.2)
III 416 (16.2) 257 (15.7)
Stent type, n (%) 0.001
Sirolimus eluting 1335 (52.0) 638 (39.0)
Paclitaxel eluting 674 (26.2) 765 (46.8)
Zotarilimus eluting 205 (8.0) 92 (5.6)
Other drug eluting 355 (13.8) 139 (8.5)
Stent diameter, mm 3.170.41 3.180.38 0.351
Stent length, mm 25.276.03 25.656.39 0.052
Total stents per patient, n 1.350.67 1.530.81 0.001
Postprocedure TIMI flow grade 0.703
0 26 (1.0) 18 (1.1)
I 17 (0.7) 8 (0.5)
II 117 (4.6) 65 (4.0)
III 2409 (93.8) 1543 (94.4)
LAD indicates left anterior descending artery; RCA, right coronary artery;
LCx, left circumflex; and TIMI, Thrombolysis in Myocardial Infarction.
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characteristics. In addition, these 2 groups also had nearly
similar baseline angiographic and PCI procedural character-
istics, except that the patients in the triple group were more
likely to have single-vessel and left main disease but less
likely to have 2- and 3-vessel disease. Moreover, patients in
the triple group were more likely to receive paclitaxel-eluting
stents but less likely to receive sirolimus-eluting stents than
those in the dual group. The triple group also had higher total
numbers of stents per patient and longer stents than the dual
group (Table 2).
The in-hospital medications are listed in Table 3. Patients
in the triple group were more likely to receive glycoprotein
IIb/IIIa receptor blockers and angiotensin-converting enzyme
inhibitors but less likely to receive calcium channel blockers
than those in the dual group.
In-hospital clinical outcomes showed that the triple group
had significantly lower incidences of cardiac death and total
death than the dual group. The incidences of recurrent
myocardial infarction and major bleeding events were similar
between these 2 groups (Table 4).
The clinical outcomes at 8 months also showed that the
triple group had a significantly lower incidence of cardiac
death, total death, and total MACEs than the dual group.
However, the incidences of recurrent myocardial infarction,
coronary artery bypass grafting, repeated PCI, and TLR were
similar between the 2 groups (Table 4).
Multivariable Cox regression analysis showed that the
triple group had significantly lower incidences of in-hospital
cardiac death and total death than the dual group. The
adjusted clinical outcomes at 8 months also showed that the
triple group had significantly lower incidences of cardiac
death, total death, and total MACEs (Table 5 and Figure 2).
Subgroup analysis showed that female patients in the triple
group had significantly lower incidences of cardiac death,
total death, and total MACEs at 8 months compared with the
women in the dual group, whereas male patients in the triple
group showed only a significantly lower incidence of total
death than the dual group. Among 65-year-old patients, the
triple group had a significantly lower incidence of cardiac
death at 8 months and had a trend toward lower incidences of
total death and total MACEs than the dual group. However,
among 65-year-old patients, the triple group had a trend
only toward lower incidence of total death than the dual
group. Among diabetics, the triple group had significantly
lower incidences of repeated PCI and total MACEs and a
trend toward a lower incidence of cardiac death than the dual
group. However, in nondiabetic patients, although the triple
group had a significantly lower incidence of total death and a
trend toward lower incidence of cardiac death than the dual
group, the incidences of repeated PCI and total MACE were
similar between these 2 groups (Figure 3).
Discussion
The major finding of the present study is that compared with
traditional dual antiplatelet therapy, triple antiplatelet therapy
with additional cilostazol significantly lowered the incidences





(n1634), n (%) P
In-hospital outcomes
Cardiac deaths 61 (2.4) 21 (1.3) 0.013
Total deaths 88 (3.4) 36 (2.2) 0.022
Recurrent MI 6 (0.2) 6 (0.4) 0.429
Major bleeding events 10 (0.4) 3 (0.2) 0.242
Outcomes at 8 mo
Cardiac deaths 83 (3.2) 33 (2.0) 0.019
Total deaths 125 (4.9) 51 (3.1) 0.006
Recurrent MI 9 (0.4) 7 (0.4) 0.689
CABG 4 (0.2) 2 (0.1) 1.000
Repeated PCI 101 (3.9) 61 (3.7) 0.745
TLR 29 (1.1) 27 (1.7) 0.149
Total MACEs 240 (9.3) 124 (7.6) 0.049
CABG indicates coronary artery bypass grafting.





(n1634), n (%) P
Glycoprotein IIb/IIIa
receptor blocker*
290 (11.3) 369 (22.6) 0.001
Low–molecular-weight
heparin*
864 (33.6) 553 (33.8) 0.888
Unfractionated heparin* 1705 (66.4) 1081 (66.2) 0.888
-Blockers 1970 (76.7) 1273 (77.9) 0.357
Angiotensin-converting
enzyme inhibitors
1760 (68.5) 1232 (75.4) 0.001
Angiotensin II receptor
blockers
336 (13.1) 220 (13.5) 0.720
Calcium channel blockers 279 (10.9) 129 (7.9) 0.002
Statins 2085 (81.2) 1335 (81.7) 0.660
*Used only during in-hospital period.
Table 5. Adjusted Cumulative Clinical Outcomes at 8 Months
of Triple Compared With Dual Antiplatelet Therapy








Cardiac deaths 0.53 (0.32–0.88) 0.014 0.44 (0.24–0.80) 0.007
Total deaths 0.63 (0.43–0.94) 0.024 0.59 (0.36–0.94) 0.026
Recurrent MI 1.57 (0.51–4.89) 0.433 0.96 (0.28–3.35) 0.954
Outcomes at
8 mo
Cardiac deaths 0.62 (0.41–0.93) 0.021 0.52 (0.32–0.84) 0.007
Total deaths 0.63 (0.45–0.88) 0.006 0.60 (0.41–0.89) 0.010
Recurrent MI 1.22 (0.45–3.29) 0.689 0.72 (0.24–2.20) 0.565
CABG 0.78 (0.14–4.29) 0.781 0.99 (0.15–6.45) 0.990
Repeated PCI 0.95 (0.68–1.31) 0.745 0.83 (0.59–1.18) 0.312
TLR 1.47 (0.87–2.49) 0.151 1.12 (0.63–1.98) 0.694
Total MACEs 0.80 (0.64–0.99) 0.049 0.74 (0.58–0.95) 0.019
OR indicates odds ratio; CABG, coronary artery bypass grafting.
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of cardiac death, total death, and total MACEs at 8 months
in patients with acute STEMI who underwent primary PCI
with DES.
The recent updated guideline of post-PCI antiplatelet
treatment for patients who undergo PCI with DES recom-
mends administration of dual antiplatelet therapy with aspirin
and clopidogrel for at least 12 months.3 But, is it enough,
especially in the setting of AMI? Some previous studies
suggested that as high as 20% to 50% patients did not react
positively to aspirin or clopidogrel and that these patients
exhibited significantly higher risks of recurrent cardiovascu-
lar events.4–6,19 Muller and colleagues20 reported that even a
large loading dose (600 mg) of clopidogrel did not inhibit the
aggregation and degranulation of platelets by thrombin-
related activating peptides in the setting of AMI. In addition,
Gawaz et al21 showed that platelet reactivity significantly
increased in AMI patients who underwent PCI. Furthermore,
Park et al22 suggested that primary stenting with sirolimus-
eluting or paclitaxel-eluting stents in patients with AMI was
an important risk factor for acute and subacute in-stent
thrombosis. Therefore, it is reasonable to add a potent
antiplatelet agent to aspirin and clopidogrel to strengthen the
effectiveness of antiplatelet therapy in patients with acute
STEMI undergoing PCI with DES.
The present study showed that compared with dual anti-
platelet therapy, triple antiplatelet therapy had a similar
Figure 2. Adjusted cumulative incidence of cardiac death (A), total death (B), and total MACEs (C) at 8 months in patients who received
triple or dual antiplatelet therapy. Variables in the multivariable Cox regression analysis included propensity scores, antiplatelet therapy
(triple versus dual), age, sex, Killip class on admission, cardiovascular risk factors (hypertension, dyslipidemia, smoking, diabetes melli-
tus, family history of coronary heart disease), prior myocardial infarction, chronic heart failure and prior cerebrovascular disease, periph-
eral arterial disease, stent type, number of diseased vessels, and cardiovascular medications (glycoprotein IIb/IIIa receptor blockers,
heparins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, -blockers, calcium channel blockers, and statins).
Cum. Prob. indicates cumulative probability; OR, odds ratio.
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incidence of in-hospital major bleeding events but signifi-
cantly decreased the incidences of cardiac death, total death,
and total MACEs up to 8 months. In addition, it is noted that
the event curves including cardiac death and total death
separate primarily in the first 30 days and then gradually
become linear (Figure 2), suggesting that the mortality
benefits of triple antiplatelet therapy were obtained mainly
within 30 days after AMI. However, the MACE curve
showed that the beneficial effects of triple antiplatelet therapy
appeared continuously throughout the 8 months of follow-up
(Figure 2), suggesting that the composite beneficial effects of
triple antiplatelet therapy were not limited to 30 days but
persisted up to 8 months. This result might be attributed to the
antirestenotic property of cilostazol and different pharmaco-
logical actions with aspirin and clopidogrel as demonstrated
in other studies.14–17 Our results were consistent with a
previous study from Lee et al.23 That study compared the
effects of triple antiplatelet and dual antiplatelet strategy on
stent thrombosis up to 30 days after the index procedure in all
patients who received PCI with both bare metal stents and
DES. Their results showed that compared with the dual
antiplatelet regimen, triple antiplatelet therapy seemed to be
more effective in preventing thrombotic complications after
stenting without an increased risk of side effects. However,
that study included only a relatively small number of AMI
cases (total, 573 AMI cases). Furthermore, they did not
provide a subgroup analysis in the patients with AMI. In
contrast, we evaluated in a larger scale the safety and efficacy
of triple antiplatelet therapy in STEMI patients who under-
went primary PCI with DES.
Some previous studies suggested that the administration of
cilostazol after PCI significantly lowered the incidence of
in-stent restenosis.15–17 Tsuchikane et al15 reported that
cilostazol significantly reduced the incidences of in-stent
restenosis and TLR after successful PCI. Douglas et al16 also
reported that treatment with cilostazol resulted in a signifi-
cantly larger minimal luminal diameter and a significantly
lower binary restenosis rate compared with placebo-treated
Figure 3. Adjusted odds ratios (ORs) for 8-month incidence of cardiac death (A), total death (B), TLR (C), repeated PCI (D), or total
MACEs (E) associated with triple antiplatelet therapy in the entire study population and various subgroups of patients according to sex,
age, and diabetes mellitus (DM).
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patients and that these favorable effects were apparent in
patients at high risk for restenosis.
However, in the present study, although we found that the
treatment of cilostazol significantly improved clinical out-
comes at 8 months, we did not find the extra beneficial effects
of cilostazol on the TLR and repeated PCI in overall study
population. Recently, Lee et al18 reported a randomized study
comparing triple and dual antiplatelet therapy in angina
patients with diabetes mellitus who received DES. Their
results showed that triple antiplatelet therapy after DES
implantation decreased the extent of late loss and the inci-
dence of 9-month TLR. In the present study, the subgroup
analysis performed in diabetic patients showed that although
the incidence of TLR was similar between the triple and dual
groups, the incidence of repeated PCI was significantly
reduced in diabetic patients. We speculate that the difference
between our study and that of Lee et al18 might be due to the
different study populations and follow-up regimens. In the
present study, we routinely performed only clinical follow-
up. Some patients with angiographic in-stent restenosis might
be asymptomatic and would not be found in routine clinical
follow-up. This may be an important reason for the similar
incidences of TLR between the triple and dual groups in our
study. Cilostazol has pleiotropic effects on preventing the
progression of atherosclerosis.24,25 Nakamura et al24 reported
that treatment with cilostazol in type 2 diabetic patients with
peripheral arterial disease could induce some beneficial
changes in serum lipid profile and plasma fatty acid compo-
sition. These mechanisms might be associated with the
reduction in repeated PCI observed in diabetic patients in the
present study.
Study Strengths and Limitations
The strengths of the KAMIR study include its prospective
design and large multicenter population base. The registry
provides a comprehensive view of the contemporary treat-
ments and outcomes in the Asian patients with AMI in the era
of DES.
The present study has some limitations. First, although
there is a large number of subjects in the present study,
because of the nonrandomized nature of the registry study,
there were baseline differences in several important prognos-
tic factors between our primary comparison groups. Although
we included most confounders in the multivariable Cox
regression model, including propensity score to control the
baseline biases, it is possible that some potential confounders
might have crept in. However, this multicenter registry may
help complete the picture gained from randomized trials,
which usually have highly selected patients treated in a
nonroutine setting. Second, in the present study, we divided
patients into different antiplatelet therapies on the basis of
their in-hospital, discharge, and follow-up medical records,
but we did not collect information on adverse reactions to
cilostazol during the follow-up period. However, we have
detailed information on the major and minor bleeding events,
mortality, and recurrent myocardial infarction, which also are
very important components of safety profiles and can help us
understand the main safety profiles of cilostazol.26 Fortu-
nately, a recent study showed that the adverse reactions in
patients who received triple antiplatelet therapy were similar
to those who received dual therapy.18 Third, because we did
not collect data on cardioactive medications, including
-blockers, statins, angiotensin-converting enzyme inhibi-
tors, and angiotensin II receptor blockers, during the
follow-up period, this also might be a confounding factor.
Conclusions
The present study showed that aggressive antiplatelet treat-
ment with aspirin, clopidogrel, and cilostazol not only had a
good safety profile but also improved midterm clinical
outcomes in acute STEMI patients who underwent primary
PCI in the era of DES. Notably, female patients, old patients,
and diabetic patients seemed to get more benefits from the
triple antiplatelet therapy. Therefore, these results might
provide the rationale for the use of triple antiplatelet therapy
in these patients. Because of the limitations of the registry
study, a randomized trial designed to compare triple and dual
antiplatelet therapy in these patients is needed.
Appendix
KAMIR Investigators
The complete list of KAMIR Investigators follows: Myung Ho
Jeong, MD; Young Jo Kim, MD; Chong Jin Kim, MD; Myeong
Chan Cho, MD; Young Keun Ahn, MD; Jong Hyun Kim, MD; Shung
Chull Chae, MD; Seung Ho Hur, MD; In Whan Seong, MD; Taek
Jong Hong, MD; Dong Hoon Choi, MD; Jei Keon Chae, MD; Jae
Young Rhew, MD; Doo Il Kim, MD; In Ho Chae, MD; Jung Han
Yoon, MD; Bon Kwon Koo, MD; Byung Ok Kim, MD; Myoung
Yong Lee, MD; Kee Sik Kim, MD; Jin Yong Hwang, MD; Seok Kyu
Oh, MD; Nae Hee Lee, MD; Kyoung Tae Jeong, MD; Seung Jea
Tahk, MD; Jang Ho Bae, MD; Seung Woon Rha, MD; Keum Soo
Park, MD; Kyoo Rok Han, MD; Tae Hoon Ahn, MD; Moo Hyun
Kim, MD; Ju Young Yang, MD; Chong Yun Rhim, MD; Hyeon
Cheol Gwon, MD; Seong Wook Park, MD; Young Youp Koh, MD;
Seung Jae Joo, MD; Soo Joong Kim, MD; Dong Kyu Jin, MD; Jin
Man Cho, MD; Jeong Gwan Cho, MD; Wook Sung Chung, MD;
Yang Soo Jang, MD; Ki Bae Seung, MD; and Seung Jung Park, MD.
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CLINICAL PERSPECTIVE
Drug-eluting stent implantation in acute myocardial infarction is associated with an increased risk for acute and subacute
in-stent thrombosis. Increased platelet activity also has been observed in acute myocardial infarction. Therefore, more
aggressive antiplatelet therapy rather than conventional dual antiplatelet therapy may offer extra benefits for acute
myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. This article
retrospectively evaluates the safety and efficacy of triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol;
n1634) and dual antiplatelet therapy (aspirin plus clopidogrel; n2569) in 4203 ST-segment elevation myocardial
infarction patients who underwent primary percutaneous coronary intervention with drug-eluting stents. Selection of
patients for treatment with triple antiplatelet therapy was left to the physician’s discretion. Compared with dual antiplatelet
therapy, triple antiplatelet therapy had a similar incidence of major bleeding events but a significantly lower incidence of
in-hospital mortality. After adjustment for known confounders, triple antiplatelet therapy had significantly lower incidences
of cardiac death (adjusted odds ratio, 0.52; 95% confidence interval, 0.32 to 0.84; P0.007), total death (adjusted odds
ratio, 0.60; 95% confidence interval, 0.41 to 0.89; P0.010), and total major adverse cardiac events (adjusted odds ratio,
0.74; 95% confidence interval, 0.58 to 0.95; P0.019) at 8 months than dual antiplatelet therapy. In this large, real-world
clinical study in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary
intervention with drug-eluting stents, triple antiplatelet therapy not only had a good safety profile but also improved
midterm clinical outcomes. Randomized trials are needed to compare the safety and efficacy of the triple and dual
antiplatelet therapies in these patients.
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